VTX:NOVN

Novan Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume11.21 million shs

Average Volume5.98 million shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Novan, Inc., a clinical development-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology product candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, a topical anti-viral product candidate. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was founded in 2006 and is headquartered in Morrisville, North Carolina.

MarketRank^™

Overall MarketRank^™

1.26 out of 5 stars

4.2 Analyst's Opinion

Consensus Rating
Novan has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 7 buy ratings, 4 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of CHF 94.08, Novan has a forecasted upside of ∞ from its current price of CHF 0.
Amount of Analyst Coverage
Novan has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.1 Community Rank

Outperform Votes
Novan has received 270 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Novan has received 372 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Novan has received 57.94% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote “Outperform” if you believe NOVN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Novan does not currently pay a dividend.
Dividend Growth
Novan does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novan insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange VTX

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolVTX:NOVN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.novartis.com

Phone+41-61-3241111

Employees24

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A

Market CapN/A

Next Earnings DateN/A

OptionableNot Optionable

30 days | 90 days | 365 days | Advanced Chart

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.

Novan (VTX:NOVN) Frequently Asked Questions

Is Novan a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 2 sell ratings, 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novan stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NOVN, but not buy additional shares or sell existing shares.
View analyst ratings for Novan or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Novan?

Wall Street analysts have given Novan a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novan wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for NOVN?

13 brokers have issued 12 month target prices for Novan's stock. Their forecasts range from CHF 75 to CHF 109. On average, they expect Novan's stock price to reach CHF 94.08 in the next year.
View analysts' price targets for Novan or view Wall Street analyst' top-rated stocks.

Who are some of Novan's key competitors?

Some companies that are related to Novan include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena plc (ABZA.L) (ABZA), Acrux Limited (ACR.AX) (ACR), Actinogen Medical Limited (ACW.AX) (ACW), AdAlta Limited (1AD.AX) (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Alaric (HALB) and Algernon Pharmaceuticals (AGNPF).
View all of NOVN's competitors.

What other stocks do shareholders of Novan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Novartis (NVS), General Motors (GM), IAMGOLD (IAG), (DGI) (DGI), The Walt Disney (DIS), Bank of America (BAC), The Coca-Cola (KO), Merck & Co., Inc. (MRK), NovaGold Resources (NG) and NIKE (NKE).

Who are Novan's key executives?

Novan's management team includes the following people:

Ms. Paula Brown Stafford, Pres, CEO & Chairwoman (Age 55, Pay $450.48k)
Mr. John M. Gay, Chief Financial Officer (Age 44, Pay $255.81k)
Mr. Robert Alexander Ingram, Exec. Director (Age 78, Pay $70k)
Mr. Andrew J. Novak, VP of Accounting & Bus. Operations and Chief Accounting Officer
Dr. Carri Geer, Sr. VP & CTO
Cole Ikkala, Director of Investor Relations, Communications & Bus. Devel.
Mr. Stanley Hollenbach BS, J.D., Sr. VP of R&D
Ms. Elizabeth Messersmith, Sr. VP & Chief Devel. Officer

What is Novan's stock symbol?

Novan trades on the VTX under the ticker symbol "NOVN."

What is Novan's official website?

The official website for Novan is www.novartis.com.

How can I contact Novan?

Novan's mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111.

This page was last updated on 1/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Novan Stock Forecast, Price & News

Adding

Adding

Adding Novan, Inc.

MarketRank™

Overall MarketRank™